摘要
背景与目的:目前对子宫内膜癌的早期筛查及疾病监测仍缺少有效的肿瘤监测指标。本文旨在探讨肿瘤标志物CA125及人附睾分泌蛋白4(human epididymis protein 4,HE4)单项或联合检测对诊断子宫内膜癌患者的临床意义。方法:选择80例具有肿瘤标志物检测结果的子宫内膜癌患者和27例子宫良性肿瘤患者的临床资料进行回顾性分析。结果:子宫内膜癌患者血清HE4水平为(92.32±7.60)pmol/L,子宫良性肿瘤患者血清HE4水平为(58.88±3.01)pmoL/L;以上2组CAl25水平分别为(30.05±5.24)、(34.32±8.16)U/mL。子宫内膜癌患者血清HE4水平明显高于子宫良性肿瘤患者,差异有统计学意义(P<0.01),而CA125水平差异无统计学意义(P>0.05)。HE4和CA125单项检测的ROC-AUC值分别为0.731和0.503,差异有统计学意义(P<0.001)。两项指标联合检测的ROC-AUC值为0.758,与单项指标检测相比,差异有统计学意义(P<0.001)。特异度为95%的情况下,CA125单项检测的灵敏度为10%,HE4单项检测的灵敏度为32.5%,而联合检测的灵敏度为33.8%。结论:HE4是检测子宫内膜癌肿瘤较理想的标志物,其血清水平对子宫体肿瘤的良恶性辅助诊断及鉴别诊断具有一定的应用价值,联合CA125检测可以提高对子宫内膜癌的诊断率。
Background and purpose： To date, there is no good marker for screening or disease monitoring of endometrial carcinoma. The present study aimed to investigate the significance of human epididymis protein 4 （HE4） as a tumor marker combined with CA125 in diagnosis of endometrial carcinoma patients. Methods： Serum levels of HE4 and CA125 were examined in 80 patients with endometrial carcinoma. Twenty-seven patients with benign uterus disease were used as controls. Results： Serum levels of HE4 in endometrial carcinoma group were significantly higher than those in the benign uterus disease group （92.32±7.60 pmol/L vs 58.88±3.01 pmol/L, P〈0.0001）, while the difference of these CA125 levels have no statistical meaning （30.05±5.24 U/mL vs 34.32±8.16 U/mL, P〉0.05）. The receiver operating characteristic area under the curve （ROC-AUC） were 0.731, 0.503 and 0.758, the sensitivity were 32.5%, 10% and 33.8% when the specificity was 95% in HE4 alone, CA125 alone and HE4＋CA125 combined detection in endometrial cancer group. Conclusion： HE4 is an ideal tumor marker and it has certain values in accessory diagnosis and differential diagnosis of endometrial cancer. The clinical value can be improved by combined detection of HE4 and CA125.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2012年第11期820-824,共5页
China Oncology
